ѻý-Site Updates
/index.html
English News Release,Information,Latest News.RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH “TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA
/news/2024/news202467.html
ѻý's news release RELEASE OF DEMENTIA DISEASE AWARENESS VIDEO FOR WORLD ALZHEIMER’S MONTH “TODAY FOR TOMORROW”: A DOCUMENTARY OF SIX MONTHS FOLLOWING THE CURRENT STATE OF DEMENTIA is posted. 2024-09-17T10:00:00+09:00LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
/news/2024/news202466.html
ѻý's news release LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) in Combination With Transarterial Chemoembolization (TACE) Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma is posted. 2024-09-17T08:30:00+09:00Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models)
/news/2024/news202465.html
ѻý's news release Investigator-initiated clinical studies to be launched following confirmation of tumor shrinkage induced by the targeted protein degrader E7820 using J-PDX (Japanese cancer patient-derived tissue transplantation models) is posted. 2024-09-12T16:07:24+09:00EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024
/news/2024/news202464.html
ѻý's news release EISAI ACCELERATES PROGRESS IN ONCOLOGY RESEARCH WITH NEW DATA AT ESMO CONGRESS 2024 is posted. 2024-09-05T08:30:00+09:00ѻý Announces Status Relating to Acquisition of Own Shares
/news/2024/news202463.html
ѻý's news release ѻý Announces Status Relating to Acquisition of Own Shares is posted. 2024-09-02T11:30:00+09:00RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN’S AUTUMN SLEEP HEALTH WEEKS
/news/2024/news202462.html
ѻý's news release RELEASE OF INSOMNIA AWARENESS VIDEO FOR JAPAN’S AUTUMN SLEEP HEALTH WEEKS is posted. 2024-08-27T09:00:00+09:00 Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain
/news/2024/news202461.html
ѻý's news release Leqembi® (lecanemab) Authorized for Early Alzheimer’s Disease in Great Britain is posted. 2024-08-22T18:05:00+09:00“LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates
/news/2024/news202460.html
ѻý's news release “LEQEMBI®” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in the United Arab Emirates is posted. 2024-08-14T08:00:00+09:00Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation
/news/2024/news202459.html
ѻý's news release Update Regarding the Regulatory Status of LEQEMBI® Subcutaneous Formulation is posted. 2024-08-06T10:40:00+09:00IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2025 [Material, Webcast]”
/ir/library/presentations/index.html
ѻý's latest news IR “First Quarter Financial Results Briefing for the Fiscal Year Ending March 31, 2025 [Material, Webcast]” is posted. 2024-08-05T12:35:00+09:00IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2025”
/ir/library/settlement/index.html
ѻý's latest news IR “First Quarter Financial Report for the Fiscal Year Ending March 31, 2025” is posted. 2024-08-02T12:35:00+09:00REVENUE OF LEQEMBI® (PRELIMINARY BASIS)
/news/2024/news202458.html
ѻý's news release REVENUE OF LEQEMBI® (PRELIMINARY BASIS) is posted. 2024-08-01T19:45:00+09:00ѻý Announces Status Relating to Acquisition of Own Shares
/news/2024/news202457.html
ѻý's news release ѻý Announces Status Relating to Acquisition of Own Shares is posted. 2024-08-01T11:30:00+09:00IR "Presentation Materials at The Alzheimer’s Association International Conference (AAIC) 2024"
/ir/library/presentations/index.html
ѻý's latest news IR "Presentation Materials at The Alzheimer’s Association International Conference (AAIC) 2024" is posted. 2024-07-31T08:00:00+09:00New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024
/news/2024/news202456.html
ѻý's news release New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at AAIC 2024 is posted. 2024-07-31T08:00:00+09:00